Clinical Trial

Functional Impairment in Albinism

Study acronym: PLAIB
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 13, 2025 (before its estimated October 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
Albinism is a genetic and hereditary anomaly that affects pigmentation. This pathology is characterized by a deficit in melanin production. In humans, the clinical diagnosis of albinism is based on a number of factors, including : * In the integumentary region: fair skin tone, with white hair, eyelashes and eyebrows. * Ophthalmological: reduced visual acuity, photophobia, nystagmus, transilluminated blue irises, hypopigmentation of the retina at the back of the eye with fovea plana. As treatment options begin to emerge for certain albinism-induced anomalies (including, for example, the depigmentation that causes photophobia), it is desirable to understand what these patients' complaints are, and to gather their views on the emergence of treatments targeting just one of their complaints, namely glare.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-03-28.
Status change: Not Yet Recruiting → Recruiting 2025-02-11
Trial Details
NCT Number NCT06345976
Lead Sponsor Fondation Ophtalmologique Adolphe de Rothschild
Conditions Albinism, Ocular
Enrollment 50 participants
Start Date 2024-10-01
Primary Completion 2025-10-01 (estimated)
Study Completion 2025-10-01 (estimated)
Updated on ClinicalTrials.gov 2025-02-13